Paper Details
- Home
- Paper Details
A 24-week randomized clinical trial investigating the efficacy and safety of two doses of etanercept in nail psoriasis.
Author: BerardescaE, BraultY, GalloG, GermainJ M, MarinoV, OrtonneJ P, PaulC
Original Abstract of the Article :
BACKGROUND: Nail psoriasis is common in patients with psoriasis and can seriously affect their quality of life. Current treatments are limited and there is no standard course of therapy. OBJECTIVES: To assess the efficacy and safety of etanercept (ETN) on nail psoriasis in patients with moderate-to...See full text at original site
Dr.Camel's Paper Summary Blogラクダ博士について
ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。
* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。
引用元：
https://doi.org/10.1111/bjd.12060
データ提供：米国国立医学図書館（NLM）
The Nail-Biting Truth About Etanercept: A New Hope for Nail Psoriasis
The realm of dermatology is constantly evolving, and nail psoriasis presents a particularly challenging puzzle. This research, a 24-week randomized clinical trial, delves into the efficacy and safety of etanercept (ETN) for treating nail psoriasis. Like a seasoned explorer navigating a vast desert, researchers meticulously compared two different dosing regimens of ETN, seeking the optimal route to alleviate this condition. They discovered that both regimens effectively tackled nail psoriasis, offering a beacon of hope for patients who had previously struggled with conventional treatments.
Etanercept Shows Promise: A Double Dose of Good News
The study revealed that both dosing regimens of ETN, administered twice weekly for 12 weeks followed by once weekly for 12 weeks (BIW/QW group) and once weekly for 24 weeks (QW/QW group), demonstrated significant improvements in the Nail Psoriasis Severity Index (NAPSI). The NAPSI scores plummeted by an average of 4.3 points in the BIW/QW group and 4.4 points in the QW/QW group after 24 weeks. This reduction in NAPSI scores signifies a remarkable improvement in the severity of nail psoriasis. Think of it as a vast desert landscape slowly turning green and lush.
Etanercept: A Oasis in the Desert of Nail Psoriasis
The findings suggest that ETN may be a valuable tool in the fight against nail psoriasis, offering a glimmer of hope for patients struggling with this condition. ETN’s effectiveness in treating nail psoriasis is a significant development, and its well-tolerated nature further enhances its appeal. While the journey to a complete cure may be long, ETN offers a promising path for those seeking relief from the discomfort and impact of nail psoriasis.
Dr. Camel's Conclusion
This study is like discovering a hidden oasis in the vast desert of nail psoriasis research. Etanercept, with its dual dosing options, offers a refreshing respite for those struggling with this condition. While further research is needed to fully understand the long-term effects, this study provides valuable insights into the potential of etanercept as a treatment for nail psoriasis.
Date :
- Date Completed 2013-11-13
- Date Revised 2022-03-16
Further Info :
Related Literature
English
This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.